While the oncology team has been delivering on Abecma, the severe genetic disease team met the moment. It has been an amazing journey and in many ways, we’re just getting started. "We and our colleagues at BMS are now full speed ahead and on track to begin treating patients this quarter. "Undoubtedly the highlight of last quarter at bluebird was the approval of Abecma, the first and only CAR T therapy approved for the treatment of relapsed or refractory multiple myeloma," said Nick Leschly, chief bluebird. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended Maand shared recent operational progress.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |